Gelesis Holdings, Inc

Gelesis is a biotechnology company based in Boston, MA, specializing in the development of innovative therapies for gastrointestinal (GI)-related chronic diseases. Their unique approach involves the use of superabsorbent hydrogels that mimic the properties of raw vegetables, which are administered in capsule form to act locally in the stomach and intestines. Their portfolio includes an FDA-cleared product, Plenity, designed to aid in weight management, as well as potential therapies in development for Type 2 Diabetes, Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH), and Functional Constipation.

Gelesis' hydrogel technology platform offers a safe and convenient alternative for individuals seeking weight management solutions without resorting to surgery or stimulants. By increasing the volume and firmness of consumed foods while reducing caloric density, their products help empower people to improve their diet, lifestyle, and overall health. With a focus on biomimicry and utilizing naturally-derived building blocks, Gelesis is at the forefront of developing groundbreaking treatments for GI-related chronic diseases.

Generated from the website